
Opinion|Videos|July 19, 2024
EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
- What was the objective of the subgroup analysis of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- N=165
- N=24 aged ≥75 years
- N=20 ISS stage III
- N=38 high-risk cytogenetics
- N=28 extramedullary disease
- N=18 bone marrow plasma cells
- N=50 penta-drug refractory
- Median follow up ~30 months across subgroups
- Objective Response Rate (ORR)
- Median duration of response (mDOR)
- Safety
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement
Trending on AJMC
1
Health Equity & Access Weekly Roundup: November 20, 2026
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
4
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
5

